X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AdVEGFXC1
Therapeutic Area: Cardiology/Vascular Diseases Product Name: XC001
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Fountain Healthcare Partners
Deal Size: $41.9 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 22, 2021
Details:
The financing will enable XyloCor to expand its clinical development program for XC001, including the initiation of a new trial of XC001 as a potential adjunctive therapy to augment the effectiveness of coronary artery bypass graft surgery (CABG).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TOTUM-070
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TOTUM-070
Highest Development Status: Phase I/ Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
TOTUM-070 is a combination of plant extracts that contains neither phytosterols nor red yeast rice, designed by VALBIOTIS’ proprietary R&D platform based in Riom (63).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): XC001
Therapeutic Area: Cardiology/Vascular Diseases Product Name: XC001
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
Details:
XyloCor dosed the first two patients in the EXACT Trial, a Phase 1/2 dose escalation trial evaluating the safety, tolerability and efficacy of its lead candidate XC001 in patients with refractory angina.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ITI214
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ITI-214
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
Details:
In this study, ITI-214 improved cardiac output by increasing heart contractility and decreasing vascular resistance.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Danicamtiv
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-491
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2020
Details:
Danicamtiv is MyoKardia’s lead activator candidate designed to increase the contractility of the heart with minimal or no effect on myocardial relaxation and compliance (diastolic function) by acting directly on the proteins in the heart muscle responsible for contraction.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
